首页 News 正文

Pfizer's new generation of specific migraine treatment drug, Loctite, has been approved in China

芊芊551
235 0 0

Pfizer announced on January 26th that its new generation of specific migraine treatment drug, Letaike (Rimezepam orally disintegrating tablets), has been approved by the National Medical Products Administration for the acute treatment of migraines in adults with or without aura.
According to Pfizer, this product is a calcitonin gene related peptide (CGRP) receptor antagonist using orally disintegrating tablet technology, which can effectively block the key pathways related to migraine onset, quickly and continuously alleviate headaches and related accompanying symptoms, and has no contraindications to cardiovascular diseases.
Jean Christophe Pointeau, Senior Vice President of Pfizer Global and President of Pfizer China, stated that Remdesipam Orally Invasive Tablets is the first next-generation migraine specific treatment drug to enter China. With CGRP as the treatment target and innovative Orally Invasive Technology, it solves the problem of insufficient drug efficacy and safety in the field of migraine treatment in the past.
"As the only CGRP receptor antagonist orally disintegrating tablets in the world to date, Rimezepam orally disintegrating tablets have brought new breakthroughs in the treatment of migraines, bringing new treatment options for Chinese clinical doctors and patients," he introduced.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

芊芊551 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    44